[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,176,0,25,[9,53,83,109,140,159,184,216,250,275,301,324,349,374,400,431,461,497,519,553,612,645,675,722,748],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100617066","effects-of-meal-macronutrients-on-postprandial-lipids-100617066",false,"NCT07313787","Effects of Meal Macronutrients on Postprandial Lipids","Prospective Cross-Over Study of the Effects of Meal Macronutrients on Postprandial Lipids","* INCLUSION CRITERIA:\n\nCommon inclusion criteria (all groups):\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>= 18 years\n2. Average alcohol intake in the past 6 months \\\u003C 3 drinks (approximately 30g) per day (male) or \\\u003C 2 drinks (approximately 20 g) per day (female)\n\nHealthy control specific inclusion criteria:\n\n1. In good general health with no known active medical conditions as evidenced by medical history\n2. Fasting glucose \\\u003C100 mg\u002FdL\n3. HbA1c \\\u003C5.7%\n4. Fasting triglycerides \\\u003C150 mg\u002FdL\n5. ALT and AST within normal limits\n6. BMI \\>=18.5 to \\\u003C25 kg\u002Fm\\^2 (or \\\u003C23 kg\u002Fm\\^2 in participants of Asian descent)\n7. Not taking any medications or supplements that, in the opinion of the investigator, would interfere with interpretation of study data.\n\nMetabolic syndrome specific inclusion criteria\n\n1. Obesity defined as either\n\n   1. BMI \\>30 kg\u002Fm\\^2 (or \\>=27 kg\u002Fm\\^2 in participants of Asian descent), OR\n   2. Elevated waist circumference as defined below:\n\n      * Country\u002FEthnic group - Europid, Sub-Saharan African, Eastern Mediterranean and Middle East (Arab):\n\n        * Sex: Male; Waist circumference: \\>=94cm\n        * Sex: Female; Waist circumference: \\>=80cm\n      * Country\u002FEthnic group - South Asian, Chinese, Japanese, Ethnic South and Central American:\n\n        * Sex: Male; Waist circumference: \\>=90cm\n        * Sex: Female; Waist circumference: \\>=80cm\n\n   Plus any 2 of the following\n2. Elevated triglycerides defined as EITHER\n\n   1. Fasting triglycerides \\>= 150 mg\u002FdL at screening, OR\n   2. Specific treatment for hypertriglyceridemia\n3. Low HDL cholesterol, defined as EITHER\n\n   1. HDL \\\u003C40 mg\u002FdL (males) or \\\u003C50 mg\u002FdL (females) at screening, OR\n   2. Specific treatment for low HDL\n4. Elevated blood pressure defined as EITHER\n\n   1. Systolic BP \\>= 130 at screening, OR\n   2. Diastolic BP \\>= 85 mm Hg at screening, OR\n   3. Treatment of previously diagnosed hypertension\n5. Elevated glucose defined as EITHER\n\n   1. HbA1c \\>= 5.7% (at screening), OR\n   2. Fasting serum glucose \\>= 100 mg\u002FdL (at screening), OR\n   3. 2-hour post-load glucose levels \\>= 140 mg\u002FdL (by history), OR\n   4. Prior diagnosis of type 2 diabetes\n\nLipodystrophy-specific inclusion criteria:\n\n1. Clinical diagnosis of generalized or partial lipodystrophy based on reduction in adipose tissue outside the normal range in some or all adipose depots (including, at a minimum, the gluteofemoral depot).\n2. Insulin resistance as defined by fasting insulin \\>22.5 or high exogenous insulin requirement (\\> 2 units per kg per day or \\> 200 units total per day) at screening.\n\nNephrotic syndrome specific inclusion criteria\n\n1. History of biopsy proven non-diabetic glomerular disease (any histology)\n2. Nephrotic range proteinuria defined by ANY of the following:\n\n   1. Protein\u002Fcreatinine ratio uPCR \\>= 3.5 g\u002Fg at screening, OR\n   2. 24 hour protein excretion \\>= 3.5 gr\u002F24hr) at screening, OR\n   3. History of nephrotic range proteinuria (as defined above) within the past 5 years but in complete (defined as proteinuria \\\u003C= 0.3 g\u002Fday or partial remission (defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria \\\u003C 3.5 g\u002Fday) based on 24 hr urine or uPCR at time of screening\n\nEXCLUSION CRITERIA:\n\nCommon exclusion criteria (all groups):\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Consuming extreme macronutrient diet (e.g., very low-carbohydrate, high fat diets such as ketogenic, \"paleo\" or Atkins diets, among others).\n2. Plans to actively gain or lose weight during the study period (other than changes in water balance as clinically needed in subjects with nephrotic syndrome).\n3. Change in body weight of \\>5% or \\>3 kg (whichever is larger) in the 3 months prior to screening (by participant report) in participants who do NOT have nephrotic syndrome.\n4. Body weight \\>450 lbs (upper limit that can be accommodated by DXA scanner).\n5. Participating in a regular strenuous exercise program (\\> 2h\u002Fweek of vigorous activity) as determined by volunteer report or evidence of vigorous exercising in order to lose weight, change body shape, or to counteract the effects of eating.\n6. Uncontrolled diabetes, defined as HbA1c \\>9% at screening.\n7. Lipemia defined as fasting or non-fasting triglycerides of \\>1000 mg\u002FdL at screening.\n8. Renal dysfunction defined as eGFR \\\u003C50 mL\u002Fmin\u002F1.73 m\\^2 at screening.\n9. In participants with liver disease, history of decompensated advanced liver disease, defined as direct bilirubin \\> 0.5 g\u002FdL, PT \\> 18 seconds, albumin \\\u003C 3 g\u002FdL, MELD score \\> 12, or history of ascites, encephalopathy, variceal bleeding, spontaneous bacterial\n\n   peritonitis or liver transplant.\n10. History of hypertriglyceridemia-induced pancreatitis within 3 months prior to screening.\n11. Positive pregnancy test or breastfeeding at screening.\n12. Clinically significant abnormalities in thyroid function, blood counts, as assessed by screening labs.\n13. Acute cardiovascular events within the past 6 months\n14. Anemia (Hgb \\\u003C10 mg\u002FdL in women or \\\u003C12 mg\u002FdL in men) at screening\n15. Food allergies or other dietary restrictions that could increase risk associated with test meals or cause the subject to be unwilling to consume test meals (i.e. celiac disease, vegan diets).\n16. Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.\n17. Subjects treated with tamoxifen, estrogens, or progestins that have not been stable for \\>4 weeks prior to screening.\n18. Blood donation in the last 2 weeks or planned blood donation during the study\n19. Subjects requiring regular transfusions for any reason.\n20. Subjects with known gastroparesis\n21. Inability to adhere to Lifestyle Considerations throughout study duration.\n22. Inability of the subject to understand and the unwillingness to sign a written informed consent document.\n23. Unwillingness to comply with all study procedures and unavailable for the duration of the study\n24. Any other condition or medication which, in the opinion of the investigator, increases risk to the subject, prevents the subject from complying with study procedures, prevents the subject from completing the study, or interferes with the interpretation of study results.","ALL","18 Years","120 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Background:\n\nAbnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome.\n\nObjective:\n\nTo learn more about how different types of foods affect fat levels in the blood.\n\nEligibility:\n\nPeople aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal.\n\nParticipants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after.\n\nParticipants will have other tests during their stays:\n\n* A resting metabolic test captures the air they exhale and measures how much energy they use at rest.\n* A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have.\n* A Fibroscan is a special type of ultrasound of the liver.\n* A body surface scan uses lasers to measure the total area of the body.\n* A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body.\n\nParticipants may opt to have a third visit. At this visit, the breakfast will be high in protein....",[28,29,30,31,32,33],"Nephrotic Syndrome","Lipodystrophy","Metabolic Syndrome","Healthy Volunteer","Diabetes","Metabolic Associated Steatotic Liver Disease",[35,36,37,38,39],"postprandial lipids","macronutrient","CARBOHYDRATES","FATS","Proteins","NOT_YET_RECRUITING","2026-08-20",{"date":43,"type":44},"2026-08-21","ACTUAL",{"date":46,"type":22},"2026-08-26",{"date":48,"type":22},"2031-08-01",{"name":50,"class":51},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100524721","a-randomized-comparison-of-stage-based-care-versus-risk-factor-based-care-for-prevention-of-cardiovascular-events-100524721","NCT06112418","A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events","A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events","TRANSFORM","Inclusion Criteria:\n\n1. Provided electronic or written informed consent\n2. Men \\> 55, women \\> 65 years of age\n3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and\u002For fasting glucose 100-125 mg\u002FdL \\[5.6-6.9 mmol\u002FL\\]) and\u002For metabolic syndrome. Metabolic syndrome is defined as \\> 3 of the following criteria (International Diabetes Federation 2006):\n\n   * Body mass index ≥ 27 kg\u002Fm2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)\n   * Fasting triglycerides ≥ 150 mg\u002FdL (1.7 mmol\u002FL) or treated hypertriglyceridemia\n   * HDL-cholesterol (HDL-C) \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men, \\\u003C50 mg\u002FdL (1.29 mmol\u002FL) in women or treatment for this lipid abnormality\n   * Systolic blood pressure (BP) ≥ 130 and\u002For diastolic BP≥ 85 mm Hg and\u002For treated hypertension\n   * Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or HbA1c ≥ 5.7%\n4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group\n\nExclusion Criteria:\n\n1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure\n2. Planned arterial revascularization\n3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:\n\n   1. eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator)\n   2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.\n   3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment\n   4. Weight \\> 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site\n   5. Inability to hold breath for \\> 10 seconds\n   6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \\> 80 beats per minute at screening or prior to CCTA)\n   7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA\n   8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA\n4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy \\\u003C 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)",true,"55 Years",{"count":64,"type":22},7500,[66],"NA","TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.",[69,70,30],"Diabetes Mellitus, Type 2","PreDiabetes","RECRUITING","2026-08-18",{"date":74,"type":44},"2026-08-19",{"date":76,"type":44},"2024-03-06",{"date":78,"type":22},"2029-03-05",{"name":80,"class":81},"Cleerly, Inc.","INDUSTRY",125,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":52},"100508709","air-pollution-and-cardiovascular-disease-in-qatar-an-interventional-study-to-reduce-blood-pressure-100508709","NCT05903950","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure","Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure: the APCIQ-BP Trial","APCIQ-BP","Inclusion Criteria:\n\n* Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)\n* Age ≥18 and less than 60 years old\n* Living in a single residence (home, apartment) located anywhere in Qatar\n* Mild systolic hypertension: screening visit systolic BP 130 to 159 mm Hg (off treatment or taking ≤ 2 BP medications that have been stable without changes during prior 4 weeks) plus ≥ 2 more additional criteria for the metabolic syndrome:\n\n  * Waist circumference ≥102 cm if male and ≥88 cm if female\n  * Fasting triglycerides ≥150 mg\u002FdL (or taking a triglyceride-lowering medication)\n  * HDL-C ≤ 40 mg\u002FdL if male and ≤ 50 mg\u002FdL if female (or taking an HDL-raising medication),\n  * Fasting glucose ≥100 mg\u002FdL\n\nExclusion Criteria:\n\n* Pregnancy (self-reported)\n* Screening visit urine positive for cotinine (NicAlert \\>100 ng\u002FmL)\n* Living with an active smoker who smokes indoors (by self-report)\n* High risk conditions that prohibit allowing home BP to be \\>130\u002F80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate \\\u003C 60 ml\u002Fmin)\n* A medical condition placing the participant at risk from participation (per investigators)\n* Expected overnight travel outside their residence during the study\n* HEPA filter within the air conditioners of the residence (self-reported) or individual use of HEPA filter\n* Unable to comprehend\u002Fsign an informed consent\n* Lung disease requiring oxygen\n* Cancer receiving treatment\n* Screening visit: BP ≥160\u002F100 mm Hg or fasting blood glucose ≥126 mg\u002FdL and confirmed diabetes with follow-up HbA1c ≥6.5%. If glucose is elevated ≥126 mg\u002FdL but HbA1c\\\u003C6.5%, they could still participate.\n* Medication changes in past 4 weeks. If participants are on medications for high BP or hyperlipidemia, they will need to have had stable therapy during prior 10 weeks with no planned changes during the study\n* Left upper arm circumference \\>17 inches as this will make BP levels inaccurate with the home monitor used\n* Acute illness or infectious symptoms within the prior 4 weeks.","60 Years",{"count":21,"type":22},[66],"The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.",[96,30],"Hypertension, Systolic",[98,99,100],"hypertension","metabolic syndrome","air pollution",{"date":41,"type":44},{"date":103,"type":44},"2024-11-03",{"date":105,"type":22},"2026-12",{"name":107,"class":108},"Weill Cornell Medical College in Qatar","OTHER",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100652253","phase-3-efficacy-and-safety-of-semaglutide-versus-placebo-on-cardiometabolic-profile-in-patients-with-schizophrenia-with-metabolic-syndrome-100652253","NCT07770282","Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome","Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome: A Multicentre, Double-Blind, Randomised Controlled Trial (ESCaMS Trial)","Inclusion Criteria:\n\n* Clinically diagnosed schizophrenia (ICD-11) on a second-generation antipsychotic (SGA) for more than 6 months.\n\n  * Metabolic syndrome per NCEP ATP III definition.\n  * Aged above 25 years, any gender.\n  * Patient \u002F Legally Authorised Representative (LAR) provides voluntary written informed consent.\n\nExclusion Criteria:\n\n* ● On clozapine, aripiprazole, or a combination of SGAs.\n\n  * Any contraindication to semaglutide.\n  * Comorbid severe psychiatric, medical or neurological disorder.\n  * History of organicity or significant head injury.\n  * Pregnant or breastfeeding.",{"count":117,"type":22},600,[119],"PHASE3","Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options. This multicentre, double-blind, placebo-controlled randomised trial evaluates whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability.",[122,30,123,124,125],"Schizophrenia Disorder","Antipsychotic-induced Weight Gain","Cardiovascular Risk","Insulin Resistance",[127,128,129,130,131],"Semaglutide","Metabolic syndrome","QRISK3","Cardiometabolic risk","Schizophrenia","2026-08-13",{"date":72,"type":44},{"date":135,"type":22},"2026-12-01",{"date":137,"type":22},"2030-12-30",{"name":139,"class":108},"All India Institute of Medical Sciences, Bhubaneswar",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":155,"leadSponsor":157,"locationsCount":52},"100652084","lipid-and-glucose-response-to-plant-based-and-regular-burgers-100652084","NCT07766928","Lipid and Glucose Response to Plant-based and Regular Burgers","Assessment of Postprandial Response After Consumption of Plant-based Burgers","Inclusion Criteria:\n\n* Body mass index 25 or higher\n\nExclusion Criteria:\n\n* Not diagnosed with diabetes\n* Not on any medications for glucose or lipids",{"count":148,"type":22},10,[66],"This study evaluates the blood lipid and glucose response to two burgers: 1) A plant-based meat alternative burger and 2) a regular beef burger in a cross-over trial.",[30],{"date":153,"type":44},"2026-08-17",{"date":153,"type":22},{"date":156,"type":22},"2026-12-31",{"name":158,"class":108},"University of Saskatchewan",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":167,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":183},"100651246","lifestyle-modification-for-erectile-dysfunction-in-men-with-metabolic-syndrome-100651246","NCT07758842","Lifestyle Modification for Erectile Dysfunction in Men With Metabolic Syndrome","Penile Hemodynamic Recovery Following a Six-Month Structured Lifestyle Modification Program in Men With Metabolic Syndrome-Associated Erectile Dysfunction: A Prospective Single-Arm Interventional Study","LIFE-MetS-ED","Inclusion Criteria:\n\n* Men aged 30-65 years.\n* Erectile dysfunction present for at least six months.\n* International Index of Erectile Function-5 score of 21 or less.\n* Metabolic syndrome diagnosed according to the International Diabetes Federation criteria.\n* Sexually active participants in a stable sexual relationship.\n* Willingness and ability to participate in the six-month lifestyle-modification program.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Erectile dysfunction primarily attributable to neurogenic, psychogenic, hormonal, or postsurgical causes.\n* Severe hypogonadism requiring immediate testosterone-replacement therapy.\n* Use of phosphodiesterase type 5 inhibitors, intracavernosal injections, vacuum erection devices, or other erectile-dysfunction treatment that cannot be discontinued before baseline assessment.\n* Significant penile anatomical abnormality that may interfere with penile duplex Doppler assessment, including Peyronie disease.\n* Previous pelvic surgery or pelvic radiotherapy likely to affect erectile function.\n* Severe or unstable cardiovascular disease that precludes sexual activity or participation in exercise-based lifestyle modification.\n* Uncontrolled diabetes mellitus, defined in the protocol as HbA1c greater than 10%.\n* Uncontrolled hypertension despite medical therapy.\n* Severe renal or hepatic impairment.\n* Active malignancy or life expectancy of less than one year.\n* Major psychiatric illness, cognitive impairment, or inability to comply with study procedures or follow-up.\n* Inability or refusal to provide written informed consent.","MALE","30 Years","65 Years",{"count":171,"type":22},55,[66],"Metabolic syndrome is associated with erectile dysfunction through obesity, insulin resistance, abnormal blood lipids, high blood pressure, and impaired blood-vessel function. This study will evaluate whether a structured six-month lifestyle-modification program can improve penile blood flow and erectile function in men with metabolic syndrome-associated erectile dysfunction.\n\nEligible participants will receive dietary counseling, exercise guidance, weight-management advice, smoking-cessation counseling when applicable, sleep and sedentary-behavior advice, and repeated behavioral reinforcement. Erectile function, penile blood-flow measurements obtained by penile duplex Doppler ultrasonography, body measurements, and selected metabolic laboratory parameters will be assessed before the program and after six months.",[175,30],"Erectile Dysfunction",{"date":177,"type":44},"2026-08-14",{"date":132,"type":44},{"date":180,"type":22},"2027-11-24",{"name":182,"class":108},"Al-Azhar University",2,{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":192,"maxAge":169,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":201,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":52},"100648849","digital-dietary-intervention-for-patients-receiving-glp-1-receptor-agonist-therapy-100648849","NCT07728669","Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy","Efficacy of a Digital Dietary Intervention (NutriSteppe Application) in Improving Metabolic Parameters in Adults With Type 2 Diabetes Mellitus, Obesity or Overweight With Comorbidities Who Are Receiving GLP-1 Receptor Agonist Therapy and Other Medications Prescribed Under Routine Clinical Protocols","NutriSteppe","Inclusion Criteria:\n\n* Age 21-65 years inclusive at the time of signing informed consent.\n* Male or female.\n* Overweight with at least one comorbidity, including diabetes mellitus; arterial hypertension of at least 130\u002F85 mmHg or use of antihypertensive medication; dyslipidemia defined as triglycerides of at least 1.7 mmol\u002FL, reduced HDL cholesterol below 1.0 mmol\u002FL in men or below 1.3 mmol\u002FL in women, or use of lipid-lowering medication; cardiovascular disease; respiratory or joint disease; non-alcoholic fatty liver disease; sleep disorders; or other comorbidities.\n* For participants with overweight: body mass index of 25.0-29.9 kg\u002Fm² for the Caucasian population or 23.0-27.4 kg\u002Fm² for the Asian population, together with abdominal obesity defined as waist circumference of at least 94 cm in men and 80 cm in women of the European population, or at least 90 cm in men and 80 cm in women of the Asian population.\n* Class I-III obesity where diet combined with physical activity has been ineffective, defined as weight loss of less than 5% over 3 months.\n* Class I obesity: body mass index of 30.0-34.9 kg\u002Fm² for the Caucasian population or 27.5-32.4 kg\u002Fm² for the Asian population.\n* Class II obesity: body mass index of 35.0-39.9 kg\u002Fm² for the Caucasian population or 32.5-37.4 kg\u002Fm² for the Asian population.\n* Type 2 diabetes mellitus with HbA1c of at least 6.5% (48 mmol\u002Fmol), fasting glucose of at least 6.1 mmol\u002FL in capillary whole blood or at least 7.0 mmol\u002FL in venous plasma, glucose of at least 11.1 mmol\u002FL two hours after an oral glucose tolerance test, or random glucose of at least 11.1 mmol\u002FL.\n* Body mass index of at least 25 kg\u002Fm² and no more than 40 kg\u002Fm² at screening.\n* Already receiving, or prescribed, GLP-1 receptor agonist therapy with semaglutide by the treating physician independently of the study. The study does not prescribe or modify this therapy.\n* Stable doses of medications for chronic conditions, including antihypertensive agents and statins, for at least 8 weeks before screening.\n* Ownership of an iOS or Android smartphone with internet access and willingness to download and use the \"NutriSteppe\" application if assigned to the intervention group.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Women of childbearing potential must use effective contraception throughout the study.\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus.\n* History of diabetic ketoacidosis or hyperglycemic hyperosmolar state.\n* Initiation of GLP-1 receptor agonist therapy less than 4 weeks before screening.\n* Current insulin therapy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal history of multiple endocrine neoplasia type 2 (MEN2).\n* History of acute or chronic pancreatitis.\n* Active gallbladder disease or history of gallbladder disease within 6 months before screening.\n* Severe gastrointestinal disease, including gastroparesis.\n* Major cardiovascular event within 6 months before screening, including myocardial infarction, stroke, transient ischemic attack, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention.\n* Uncontrolled arterial hypertension, defined as systolic blood pressure above 160 mmHg or diastolic blood pressure above 100 mmHg at screening.\n* Chronic kidney disease with an estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m² using the MDRD or CKD-EPI formula.\n* Severe hepatic impairment classified as Child-Pugh class C, or ALT or AST greater than three times the upper limit of normal.\n* Active malignancy or history of malignancy within 5 years, except successfully treated basal cell or squamous cell carcinoma of the skin.\n* Established HIV infection, active hepatitis B defined as HBsAg positive with detectable HBV DNA, or hepatitis C virus infection.\n* History of bariatric surgery or bariatric surgery planned during the study.\n* Anorexia nervosa, bulimia nervosa, or binge eating disorder diagnosed or active within the past year.\n* Pregnancy or breastfeeding.\n* Planning pregnancy during the study.\n* Woman of childbearing potential unwilling to use effective contraception.\n* Use of weight-loss medication, including orlistat, phentermine, combinations with topiramate, naltrexone-bupropion, or other weight-loss medication within 3 months before screening.\n* Use of systemic corticosteroids, excluding inhaled or topical corticosteroids, for more than 2 weeks within 3 months before screening.\n* Use of antipsychotic medication associated with significant weight gain unless used at a stable dose for more than 6 months.\n* Participation in another interventional clinical study within 30 days before screening.\n* Known hypersensitivity to semaglutide or any excipient.\n* No smartphone or unwillingness to use digital health technology.\n* Severe mental disorder impairing the ability to provide informed consent or comply with the protocol.\n* Active alcohol or drug dependence within the past year.\n* Any condition that, in the investigator's opinion, may compromise participant safety or the integrity of the study.","21 Years",{"count":194,"type":22},120,[66],"The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study.\n\nThe main question is:\n\nDoes the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone?\n\nThe study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety.\n\nResearchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support.\n\nParticipants in both groups will:\n\n* Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol.\n* Photograph everything they eat and drink.\n* Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study.\n* Be able to view the results of the food photograph analysis.\n\nThe photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.",[198,199,200,30],"Type 2 Diabetes Mellitus (T2DM)","Obesity (Disorder)","Overweight",[190,202,203,204,127,205,206],"Digital Dietary Intervention","Personalized Nutrition","GLP-1 Receptor Agonist","Glycated Hemoglobin","HbA1c","2026-08-10",{"date":209,"type":44},"2026-08-11",{"date":211,"type":44},"2026-07-20",{"date":213,"type":22},"2027-01",{"name":215,"class":108},"Kazakh Academy of Nutrition",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":61,"sex":222,"minAge":223,"maxAge":169,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":52},"100431064","circadian-rhythms-in-postmenopausal-women-100431064","NCT04893226","Circadian Rhythms in Postmenopausal Women","Inclusion Criteria:\n\n* postmenopausal women\n* age 45-65 years\n* prediabetic or have at least 2 features of metabolic syndrome\n\nExclusion Criteria:\n\n* on hormone therapy\n* diabetes\n* heart disease\n* alcohol consumption of \\>2 drinks per day\n* significant circadian disruption\n* having care-taking responsibilities that significantly affect sleep\n* shift work or irregular lifestyle\n* uncontrolled sleep apnea or other uncontrolled sleep disorder\n* extreme early or late chronotypes\n* significant psychiatric disorders\n* taking ADHD medications\n* diagnosed dysregulated eating behaviors\n* smoking \\>5 cigarettes\u002Fday or 30 pack-year history\n* participating in formal weight loss program\n* not weight stable","FEMALE","45 Years",{"count":225,"type":22},164,[66],"This is a randomized, parallel two-arm clinical trial design to study the efficacy of time-restricted feeding on metabolic risk in postmenopausal women, who may be particularly vulnerable to disruption of circadian eating rhythms and the associated metabolic dysfunction. It is hypothesized that time-restricted feeding will improve insulin sensitivity, glucose tolerance, body weight, and other metabolic parameters in metabolically-unhealthy postmenopausal women.",[30,229],"Postmenopausal Symptoms",[231,232,233,234,235,236,237,238,239,240,241],"postmenopause","weight","metabolic risk","glucose","body composition","lipid","sleep","prediabetes","fasting","circadian","inflammation","2026-08-07",{"date":207,"type":44},{"date":245,"type":44},"2021-10-19",{"date":247,"type":22},"2027-01-31",{"name":249,"class":108},"Julie Pendergast",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":52},"100651496","polygonatum-sibiricum-reduces-visceral-fat-in-obese-adults-100651496","NCT07759323","Polygonatum Sibiricum Reduces Visceral Fat in Obese Adults","Polygonatum Sibiricum for Visceral Obesity and Related Metabolic Abnormalities: A Randomized Controlled Trial and Mechanistic Exploration","Inclusion Criteria:\n\n* Age 18 to 65 years, male or female;\n* Body mass index (BMI) ≥ 24 kg\u002Fm², or body fat percentage ≥ 25% for males or ≥ 30% for females, and visceral fat area ≥ 100 cm²;\n* Body weight stable within the past 3 months, with fluctuation not exceeding 5%;\n* Able to understand the study content, voluntarily sign the informed consent form, and willing to complete follow-up visits and required examinations as scheduled.\n\nExclusion Criteria:\n\n* Secondary obesity (e.g., caused by endocrine disorders such as hypothyroidism, Cushing's syndrome, or polycystic ovary syndrome);\n* Previous metabolic surgery or current use of weight-loss medications;\n* Concomitant severe hyperglycemia or lipid metabolism disorders requiring immediate intensive treatment;\n* Concomitant severe cardiovascular or cerebrovascular disease, or unstable medical condition;\n* Significant hepatic or renal dysfunction (e.g., ALT or AST \\> 2-3 times the upper limit of normal, or eGFR \\\u003C 60 ml\u002Fmin\u002F1.73 m²);\n* Malignant tumors, active infections, or autoimmune diseases;\n* Use of antibiotics, probiotics, or other agents that may affect gut microbiota within the past month;\n* Pregnancy, lactation, or plans for pregnancy;\n* Allergy to or intolerance of any component of the investigational product;\n* Any other conditions deemed unsuitable for participation in this study by the investigator.",{"count":258,"type":22},66,[66],"This study is being done to find out if a traditional Chinese herb called Polygonatum sibiricum (Huangjing) can help reduce belly fat and improve metabolic health in adults with visceral obesity.\n\nVisceral obesity means having too much fat stored deep inside the belly, around the organs. This type of fat is linked to a higher risk of diabetes, fatty liver, and heart disease.\n\nThe study will include 66 adults with visceral obesity. Participants will be randomly assigned to one of two groups:\n\nOne group will receive a Polygonatum sibiricum decoction (15 grams daily) plus standard lifestyle advice on diet and exercise.\n\nThe other group will receive the same lifestyle advice only.\n\nThe study will last for 12 weeks. Researchers will measure changes in visceral fat area, body weight, waist size, blood sugar, blood lipids, and liver fat. They will also look at gut bacteria and related markers to better understand how Polygonatum sibiricum might work.\n\nParticipation involves 4 visits to the study site over the 12-week period. All participants will receive free health assessments and dietitian guidance. The study is not a treatment but a research study to test whether this herb has potential benefits for visceral obesity.",[262,30],"Visceral Obesity",[264,265],"Polygonatum sibiricum","Visceral Fat Area","2026-08-06",{"date":268,"type":44},"2026-08-12",{"date":270,"type":22},"2026-08-15",{"date":272,"type":22},"2027-07-30",{"name":274,"class":108},"Zhejiang Provincial Tongde Hospital",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":4,"leadSponsor":299,"locationsCount":52},"100143840","study-of-the-effect-of-innate-on-the-inflammatory-response-to-endotoxin-100143840","NCT01143480","Study of the Effect of Innate on the Inflammatory Response to Endotoxin","Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin","* INCLUSION CRITERIA:\n* Male or female 18 years of age or older\n* Participants must be able to understand and provide written informed consent to participate in the study\n* Participants must be able to travel to the CRU\n* Willing and able to fast after midnight the night prior to their study appointment.\n* Healthy participants as defined by the International Red Cross guidelines (Healthy means that an individual feels well and can perform normal activities. If the individual has a chronic condition such as diabetes or high blood pressure, healthy also means that they are being treated and the condition is under control).\n\nEXCLUSION CRITERIA:\n\n* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil)\n* Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit\n* Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor)\n* Use of immunosuppressants or other immune-modifying drugs \\[e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)\\], Monoclonal antibodies \\[e.g., infliximab (Remicade)\\], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone)\n* Current treatment for cancer with chemotherapy or radiation\n* Confirmed or suspected immunosuppressive or immunodeficient condition\n* GI or respiratory Illness within 5 days prior to enrollment visit, including cold or allergies\n* Smoked tobacco, chewed tobacco or used electronic cigarettes within 2 weeks prior to enrollment visit (for participants who provide a urine specimen, this will be defined by urine cotinine \\>200 ng\u002FmL at visit)\n* Alcohol consumption greater than 2 standard drinks (1 standard drink contains 15 g of ethanol) per day within the last 24 hours prior to the enrollment visit\n* Body weight \\\u003C 50 kg (\\\u003C110 lbs)\n* Temperature \\> 37.6 C; blood pressure \\\u003C 90\u002F50 mm Hg or \\> 170\u002F95 mm Hg; pulse rate \\\u003C 50 or \\>100 beats\u002Fminute\n* Pregnant or suspected pregnancy\n* Chronic Kidney Disease\n\nThe PI may review medication use on a case by case basis and make a medical determination on the participant s eligibility. In these cases, the PI determination will be documented in the participant s chart.","100 Years",{"count":284,"type":22},725,"OBSERVATIONAL","Background:\n\n\\- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers.\n\nObjectives:\n\n\\- To examine how specific genes and proteins in blood cells respond to environmental exposures.\n\nEligibility:\n\n\\- Healthy volunteers between 18 and 45 years of age.\n\nDesign:\n\n* The study will involve one visit of 45 to 60 minutes.\n* Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking.\n* Participants will provide a blood sample for research purposes.",[288,289,30,125,290],"Asthma","Atherosclerosis","Cancer",[292,293,294,31,295],"Endotoxin","Innate Immunity","Natural History","HV",{"date":242,"type":44},{"date":298,"type":44},"2012-07-30",{"name":300,"class":51},"National Institute of Environmental Health Sciences (NIEHS)",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":23,"phases":310,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":52},"100513983","phase-1-the-effect-of-sglt2-inhibition-on-adipose-inflammation-and-endothelial-function-100513983","NCT05972564","The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","SADIE2","Inclusion Criteria:\n\n1. Age 18+ years old\n2. Metabolic syndrome as defined by 3 or more of 5 criteria:\n\n   1. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmg Hg or treatment with anti-hypertensive medications for minimum of 1 month\n   2. Triglycerides ≥ 150 mg\u002FdL or treatment with a triglyceride-targeted medication (fenofibrate, gemfibrozil, niacin, high dose omega-3 fatty acids)\n   3. High-density lipoprotein (HDL) \\\u003C 40 mg\u002FdL in males or \\\u003C 50 mg\u002FdL in females\n   4. Fasting blood glucose ≥ 100mg\u002FdL or treatment with glucose-lowering medications\n   5. Waist circumference ≥ 102 cm in males or ≥ 88cm in females\n3. BMI ≥ 35 kg\u002FM2\n4. Scheduled gastric bypass or gastric sleeve in approximately 90 days (range 90-270 days)\n5. The ability to provide informed consent\n\n   Exclusion Criteria:\n6. Type 1 diabetes.\n7. Poorly controlled type 2 diabetes as defined by HbA1c ≥ 9%.\n8. Use of anti-diabetic medications other than stable dose of metformin or a sulfonylurea in the last 1 month.\n9. Treatment with a glucagon-like peptide-1 receptor agonist or co-agonist in the last 3 months.\n10. Treatment with an SGLT2 inhibitor in the last 3 months.\n11. Pregnancy or breast-feeding. Women of child-bearing potential will be required to have undergone surgical sterilization or to be using an intra-uterine device, hormonal contraceptive, or barrier methods of birth control.\n12. Cardiovascular disease such as myocardial infarction within six months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (left ventricular hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, -second- or third-degree heart block, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy\n13. Presence of implanted cardiac defibrillator or pacemaker\n14. History of serious neurologic disease such as cerebral hemorrhage, stroke, or transient ischemic attack\n15. History of pancreatitis or pancreatic surgery\n16. History or presence of immunological or hematological disorders\n17. Clinically significant gastrointestinal impairment that could interfere with drug absorption\n18. History of advanced liver disease with cirrhosis\n19. Individuals with an eGFR\\\u003C45 mL\u002Fmin\u002F1.73 m2, where eGFR is determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine is expressed in mg\u002FdL and age in years: eGFR (mL\u002Fmin\u002F1.73m2)=186 • Scr-1.154 • age-0.203 • (0.742 if female)\n20. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)\n21. Treatment with anticoagulants\n22. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult\n23. History of alcohol abuse (\\>14 per week for men and \\>7 per week for women) or illicit drug use\n24. Treatment with any investigational drug in the one month preceding the study\n25. Previous randomization in this trial\n26. Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study\n27. Inability to comply with the protocol in the opinion of the principal investigator, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study\n\n    Criteria Related to Known Adverse Effects of Drug:\n28. Uncircumcised men or men with history of balanitis\n29. History of urinary incontinence\n30. History of recurrent (\\>3) episodes of vulvovaginitis per year, or severe symptoms\n31. History of Fournier's gangrene\n32. History of recurrent (≥3) UTIs per year or pyelonephritis\n33. History of symptomatic hypotension or conditions predisposing to volume depletion\n34. Known peripheral vascular disease, neuropathy, history of foot ulcers or lower limb amputations\n35. Treatment with loop diuretics furosemide, torsemide, bumetanide, ethacrynic acid\n36. Known or suspected allergy to trial medications, excipients, or related products\n37. Contraindications to study medications, worded specifically as stated in the product's prescribing information",{"count":309,"type":22},74,[311,25],"PHASE1","Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions. This trial will determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the contribution of adipose inflammation to surrogate measures of cardiovascular disease in a randomized controlled trial of obese patients.",[314,30],"Obesity","2026-08-04",{"date":317,"type":44},"2026-08-05",{"date":319,"type":44},"2023-09-06",{"date":321,"type":22},"2026-12-30",{"name":323,"class":108},"Vanderbilt University Medical Center",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":331,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":333,"conditions":334,"keywords":340,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":52},"100624560","emotional-eating-sleep-quality-mental-state-and-metabolic-syndrome-100624560","NCT07411222","Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome","The Mediating Role of Emotional Eating and Sleep Quality in the Relationship Between Mental State and Metabolic Syndrome in Individuals With Schizophrenia and Bipolar Disorder","Inclusion Criteria:\n\n* Being registered with the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center,\n* Having a severe chronic psychiatric illness (Schizophrenia Spectrum and Other Psychotic Disorders and Bipolar Disorder) followed by the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center for at least 6 months,\n* Being in remission (Complete Remission (Pre-Remission): Symptoms remaining below threshold values for at least 2 months (8 weeks). A state of improvement lasting more than 2 months is generally referred to as \"remission\"),\n* Schizophrenia remission definition: 8 diagnostically significant symptoms were selected from the Positive and Negative Syndrome Scale.\n* Bipolar disorder remission definition: Complete remission is defined as the absence of acute attacks and the presence of minimal\u002Fvery mild symptoms.\n* Being between 18-65 years of age,\n* Being able to understand what is read and give written consent.\n\nExclusion Criteria:\n\n* Having a diagnosis of mental retardation,\n* Having other neurocognitive disorders, primarily dementia, according to DSM-V (as it can affect the ability to make decisions and give correct answers),\n* Not being able to speak or understand Turkish.",{"count":332,"type":22},78,"In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.",[131,335,336,30,337,338,339],"Bipolar Disorder","Psychiatric Issue","Emotional Eating","Sleep","Mediating",[131,335,30,337,338],"2026-07-24",{"date":343,"type":44},"2026-07-27",{"date":345,"type":44},"2026-05-30",{"date":105,"type":22},{"name":348,"class":108},"Abant Izzet Baysal University",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":223,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":52},"100609751","early-phase-1-human-cerebrovascular-blood-flow-and-sex-differences-in-metabolic-syndrome-100609751","NCT07218653","Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome","Inclusion Criteria (Healthy Controls):\n\n* 18-45 years old\n* Normal fasting values for blood glucose (less than 100 g\u002Fdl)\n* Normal values for lipids (LDL cholesterol less than 130 mg\u002Fdl, triglycerides less than 150 mg\u002Fdl) and HDL (men greater than 40, women greater than 50 mg\u002Fdl)\n* Women must have a predictable menstrual cycle. Females will be studied on cycle days 1-7 to minimize sex hormone differences and their potential confounding effects on vascular outcomes. Oral contraceptives are allowed, and women will be studied during their placebo phase.\n\nInclusion Criteria (Participants with Metabolic Syndrome):\n\n* 18-45 years old\n* Meet at least 3 of the 5 ATP MetSyn criteria. These are:\n\n  1. Waist circumference greater than 102 cm (males) or 82 cm (females)\n  2. Triglycerides greater than 150 mg\u002FdL\n  3. HDL cholesterol less than 40 mg\u002FdL (males) or 50 mg\u002FdL (females)\n  4. Blood pressure greater than or equal to 130\u002F85 mmHg\n  5. Fasting plasma glucose greater than 110 mg\u002FdL\n\nExclusion Criteria (Healthy Controls):\n\n* Body Mass Index (BMI) greater than or equal to 25 kg\u002Fm2\n* Blood pressure over 130\u002F80 mmHg\n* Meeting any of the 5 MetSyn criteria listed above.\n\nExclusion Criteria (all participants):\n\n* Current smoker, defined as more than 5 cigarettes over past 30 days\n* Current diagnosis or history of:\n\n  * peripheral vascular disease\n  * hepatic disease\n  * renal disease\n  * lung disease\n  * gastrointestinal disorders\u002Fbleeding\n  * hematologic disease\n  * stroke\n  * myocardial infarction\n  * coronary heart disease\n  * congestive heart failure\n  * heart surgery\n  * sleep apnea\n  * autoimmune diseases\n  * HIV\n  * traumatic brain injury, concussion, stroke, or seizures\n  * Asthma\n  * Polycystic ovarian syndrome\n  * Type II diabetes\n  * Currently pregnant or breastfeeding\n  * Current musculoskeletal injury\n  * Medication use known to influence cardiovascular function, other than contraceptive hormones. Broadly, the classes of drugs relate to treating blood pressure, diabetes, cholesterol.\n  * Claustrophobia\n* Lactose intolerance\n* Magnesium-restricted diet",{"count":356,"type":22},72,[358],"EARLY_PHASE1","This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Healthy Controls versus participants with MetSyn.",[30],[362,363,364,30,365],"Cerebral Blood Flow","CBF","COX","MetSyn","2026-07-23",{"date":343,"type":44},{"date":369,"type":22},"2026-08",{"date":371,"type":22},"2031-07",{"name":373,"class":108},"University of Wisconsin, Madison",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":91,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":52},"100521697","phase-2-commets--combination-mci-metabolic-syndrome-100521697","NCT06072963","COMMETS- Combination MCI Metabolic Syndrome","Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study","Inclusion Criteria:\n\n* Diagnosis of MCI (based on a MOCA \\\u003C27 and a clinical dementia rating scale \\[CDR\\] score of 0.5 representing questionable dementia).\n* Diagnosis of MetS -requiring a) abdominal obesity (waist circumference \\>102cm for men and \\>88cm for women), and b) glucose intolerance (fasting glucose\\>110 mg\u002FdL) and at least one of the following-c) dyslipidemia (high triglycerides \\[\\>150 mg\u002FdL\\] and low HDL \\[\\\u003C40mg\u002FdL for men and \\\u003C50 mg\u002FdL for women\\]), or d) elevated blood pressure (\\>130\u002F\\>85 mmHg).\n* Fluent in Hebrew\n* The study requires an active study partner\n\nExclusion Criteria:\n\n* Diabetes (of any type)\n* Taking medications that may affect glucose metabolism (including a GLP-1RA).\n* Diagnosis of dementia and its subtypes, conditions that may directly affect cognition,\n* short life expectancy or a medical condition that precludes consistent participation in the study,\n* contraindications to either insulin or Semaglutide.\n* Medications that may affect glucose metabolism such as corticosteroids.","90 Years",{"count":383,"type":22},80,[25],"The investigators propose a proof of concept RCT (randomized clinical trial), testing the efficacy of intranasal insulin (INI) with semaglutide, a combination therapy with strong biological plausibility to benefit impaired cognition through vascular mechanisms, in older adults with MetS (metabolic syndrome) and MCI (Mild Cognitive Impairment), who are enriched for cerebrovascular disease and at high dementia risk. The study will focus on cognitive and biological outcomes, allowing identification of relevant mechanisms.",[387,388,30],"Alzheimer Disease","Mild Cognitive Impairment",[390,388,128,391,127,392],"Alzheimer disease","Dementia","Intranasal insulin",{"date":343,"type":44},{"date":395,"type":44},"2024-01-30",{"date":397,"type":22},"2028-12-01",{"name":399,"class":108},"Rutgers, The State University of New Jersey",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":408,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":183},"100638613","brown-adipose-tissue-as-a-mechanistic-determinant-of-semaglutide-treatment-response-in-obesity-bat-sema-study-100638613","NCT07621640","Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)","Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET\u002FCT and Cold Stimulation Protocol","BAT-Sema","Inclusion Criteria:\n\n1. Age 20-70 years at the time of enrollment\n2. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)\n3. BMI ≥ 27 kg\u002Fm² with at least one weight-related comorbidity:\n\n   * Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication)\n   * Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication)\n   * Non-alcoholic fatty liver disease (NAFLD\u002FMASLD, confirmed by imaging or ALT\u002FAST ≥1.5× ULN)\n   * Obstructive sleep apnea (AHI ≥5\u002Fhr or clinically diagnosed)\n   * Established cardiovascular disease (CAD, stroke, PAD)\n   * Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg\u002Fm² (regardless of comorbidity)\n4. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 or type 2 diabetes mellitus\n2. History of neck surgery or radiation therapy to the neck\n3. Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents\n4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n5. Active malignancy, severe renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), severe hepatic disease, or other severe endocrine disorders\n6. Pregnancy or breastfeeding\n7. Severe psychiatric illness or cognitive impairment precluding informed consent\n8. Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants)\n9. Severe claustrophobia","20 Years","70 Years",{"count":383,"type":22},[66],"This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET\u002FCT imaging before and after 24 weeks of treatment. Prior to each PET\u002FCT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.",[314,30,414],"Brown Adipose Tissue",[416,127,417,314,418,419,420,421,422],"Brown adipose tissue","GLP-1 receptor agonist","FDG-PET\u002FCT","BAT","Biomarker","Weight loss","PDFF",{"date":424,"type":44},"2026-07-22",{"date":426,"type":22},"2026-06",{"date":428,"type":22},"2031-02",{"name":430,"class":108},"Hallym University",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":168,"maxAge":91,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":52},"100645490","a-mediterranean-diet-based-culinary-intervention-in-adults-with-metabolic-syndrome-100645490","NCT07702695","A Mediterranean Diet-Based Culinary Intervention in Adults With Metabolic Syndrome","Impact of a Mediterranean Diet-based Culinary Medicine Intervention on the Reversal of Metabolic Syndrome and Biomarkers of Inflammation, Oxidative Stress, and Aging","CUINAMET","Inclusion Criteria:\n\n* Men and women\n* Age between 30 and 60 years\n* Body mass index (BMI) between 20 and 35 kg\u002Fm²\n* Presence of metabolic syndrome defined as having at least three of the following criteria:\n\n  1. HDL cholesterol \\\u003C40 mg\u002FdL in men and \\\u003C50 mg\u002FdL in women\n  2. Fasting glucose \\>100 mg\u002FdL or use of hypoglycemic agents\n  3. Triglycerides ≥150 mg\u002FdL or use of lipid-lowering medication\n  4. Blood pressure ≥130\u002F85 mmHg\n  5. Waist circumference ≥102 cm in men and ≥88 cm in women\n\nExclusion Criteria:\n\n* Food allergies or intolerances to foods typical of the Mediterranean diet\n* Gluten intolerance or celiac disease\n* Adherence to a vegetarian or vegan diet\n* Eating disorders (including anorexia nervosa, bulimia nervosa, and binge eating disorder)\n* Moderate to severe psychiatric disorders that may compromise adherence to the intervention\n* History of cardiovascular events\n* BMI \\>35 kg\u002Fm²\n* Extreme dietary patterns in the last 3 months (e.g., Atkins diet, very high-protein diets)\n* Excessive alcohol consumption (\\>30 g\u002Fday for men and \\>20 g\u002Fday for women)\n* Pregnancy or lactation\n* Previous culinary training or formal culinary education",{"count":194,"type":22},[66],"Metabolic syndrome is a major public health concern associated with an increased risk of cardiovascular disease, type 2 diabetes, and premature mortality. The Mediterranean diet has consistently demonstrated beneficial effects on metabolic health and is recommended as a dietary strategy for the prevention and management of metabolic syndrome. However, most interventions have focused on conventional nutritional counseling and have paid limited attention to the culinary and gastronomic skills required to translate dietary recommendations into sustainable eating behaviors.\n\nThis randomized controlled trial will evaluate the effectiveness of a Mediterranean diet-based nutritional intervention complemented by culinary medicine training sessions compared with a nutritional intervention alone in Spanish adults with metabolic syndrome. The culinary medicine component is designed to enhance participants' food preparation skills, confidence in cooking, and ability to incorporate Mediterranean dietary principles into their daily lives.\n\nParticipants will be followed for 6 months to assess changes in metabolic syndrome components and other metabolic health indicators. The study aims to determine whether the integration of culinary medicine education enhances the effectiveness of conventional nutritional counseling in improving metabolic syndrome outcomes and promoting long-term adherence to a Mediterranean dietary pattern",[30],[99,444,445,446,447,448,449,241,450,451],"Mediterranean diet","culinary medicine","lifestyle intervention","diet therapy","cardiovascular risk","insulin resistance","oxidative stress","obesity","2026-07-13",{"date":454,"type":44},"2026-07-14",{"date":456,"type":22},"2026-09",{"date":458,"type":22},"2028-03",{"name":460,"class":108},"Fundacion Clinic per a la Recerca Biomédica",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":17,"minAge":408,"maxAge":91,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":477,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":52},"100645658","kodo-millet-porridge-and-its-effects-on-gut-health-and-metabolic-syndrome-100645658","NCT07703371","Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome","Impact of Dietary Fiber-Rich Kodo Millet Porridge Supplementation on Gut Microbiome and Metabolic Syndrome","KMGMS","Inclusion Criteria\n\n* Adults aged 20-60 years.\n* Willingness to provide informed consent.\n* Willingness to consume Kodo millet porridge daily for 12 weeks.\n* No planned changes in diet or physical activity during the study.\n* Overweight or obese (BMI ≥ 25 kg\u002Fm²), placing them at risk for metabolic disorders.\n\nExclusion Criteria\n\n* Known allergies to millet or any porridge ingredients.\n* Individuals who are taking on-counter dietary fiber and probiotics supplements\n* History of any chronic gastrointestinal diseases (e.g., IBD, gastritis, irritable bowel syndrome).\n* Pregnant or lactating women.\n* Antibiotic use in last 3 months.\n* Alcohol abuse, more than 2 drink per day\n* Presence and usage of medications for any serious chronic illnesses, including uncontrolled diabetes (HbA1c \\> 9), cardiovascular disease (aldosterone antagonists, alpha blockers, alpha-beta blockers, anticoagulants, antiplatelets, angiotensin-converting enzyme inhibitors, angiotensin 2 receptor blockers, beta blockers, calcium channel blockers, diuretics, digoxin) , renal disease, neurological or mental disorders, coagulation disorders, and cancer.",{"count":470,"type":22},50,[66],"Dietary fiber are components in foods that are not digested by human gastrointestinal enzymes (alpha amylase and alpha glucosidase) but are instead broken down and fermented by gut microbes. The byproducts generated during fermentation in the large intestine, primarily short-chain fatty acids (SCFA), bile acids, indoles, and their derivatives, circulate through the circulatory system to the liver, lungs, brain, adipose tissue, and muscles, where they modulate metabolism (suppress lipogenesis and alleviate insulin resistance) and immune function. Individuals who are overweight or obese frequently exhibit gut dysbiosis, characterized by lower SCFA producing commensals. This condition predisposes them to metabolic disorders such as insulin resistance, dyslipidemia, and hypertension, and contributes to conditions including type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease. Preclinical and clinical research have demonstrated that the consumption of fiber-rich foods maintains or restores gut microbiota health and diminishes the risk of metabolic disorders. Kodo millet (Paspalum scrobiculatum), a small millet, is rich in dietary fiber and we have developed a palatable kodo millet porridge beverage enriched with polyphenols and dietary fiber. The purpose of this study is to examine the effects of consuming Kodo millet porridge beverage as a nutritional supplement for 3 months, on gut microbiome richness (composition and diversity) and metabolic health in overweight or obese people.",[474,30,475,125,476],"Obesity & Overweight","Gut Dysbiosis","Dyslipidemia",[478,479,480,481,482,30,314,475,476,483,484,485,486,487,488],"Kodo Millet","Dietary Fiber","Gut Microbiome","Short-Chain Fatty Acids","16S rRNA Sequencing","Glycemia","Prebiotic","Small Millet","Porridge","Antioxidant","Inflammation","2026-07-11",{"date":454,"type":44},{"date":492,"type":44},"2026-06-01",{"date":494,"type":22},"2026-11-16",{"name":496,"class":108},"JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH",{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":222,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":52},"100645595","efficacy-of-physical-activity-program-in-metabolic-syndrome-females-with-behcet-disease-100645595","NCT07702123","Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet Disease","Inclusion Criteria:\n\n* females with metabolci syndrome\n* females with behcet disorder\n\nExclusion Criteria:\n\n* psychatric diseases women\n* mental diseased women","40 Years","50 Years",{"count":506,"type":22},40,[66],"metabolci syndrom is highly prevalent in behcet disorder females. usually physical activity is recommended to solve this problem",[30,510],"Behcet Disease","2026-07-09",{"date":454,"type":44},{"date":514,"type":44},"2026-06-02",{"date":516,"type":22},"2026-09-14",{"name":518,"class":108},"Cairo University",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":52},"100646009","atrial-cardiomyopathy-in-patients-with-cardiovascular-kidney-metabolic-syndrome-non-invasive-characterization-100646009","NCT07697469","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization","Atrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization (ATRIO-CKM)","ATRIO-CKM","Inclusion Criteria:\n\n* Adults aged 18 years or older presenting for cardiovascular evaluation Signed written informed consent Agreement with all protocol requirements\n\nExclusion Criteria:\n\n* Missing key data for ACM or CKM classification Hemodynamically significant valvular heart disease (greater than moderate severity) Mechanical or biological valve prostheses Temporary or permanent cardiac pacing Psychiatric pathology Thyroid pathology (active or untreated) Known cardiomyopathies (hypertrophic, dilated, restrictive, or infiltrative) Refusal to participate or inability to comply with protocol requirements",{"count":528,"type":22},200,"Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by pathophysiological interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multiorgan dysfunction and increased risk of atrial fibrillation, stroke, and heart failure. Atrial cardiomyopathy (ACM) - defined as any structural, contractile, or electrical abnormality of the atria - is an increasingly recognized contributor to cardiovascular morbidity and mortality in this population. Despite growing interest in both conditions, their interplay remains poorly understood, limiting effective preventive strategies and risk-stratification approaches for this high-risk group.\n\nCKM staging offers a practical framework for anticipating ACM onset and progression. Because adiposity-driven inflammation, insulin resistance, hypertension, and early kidney injury act as upstream drivers in CKM, the left atrium becomes an early indicator of hemodynamic load and fibrosis - often preceding sustained atrial fibrillation. Early non-invasive detection of ACM across CKM stages could shift care from treating complications to modifying the underlying substrate.\n\nThis prospective observational single-center cohort study aims to phenotype ACM non-invasively across all CKM stages at first diagnosis, using standard 12-lead ECG, advanced transthoracic echocardiography with speckle-tracking, a mechanistically selected biomarker panel (NT-proBNP, MR-proANP, Fetuin-A, FGF23), and cardiac MRI.\n\nAdults aged 18 years or older presenting for cardiovascular evaluation are enrolled and grouped as CKM with ACM (study group) versus CKM without ACM (control group). All participants undergo a single standardized baseline evaluation including clinical examination, 12-lead ECG with Bayés interatrial block grading, comprehensive laboratory panel, and advanced echocardiography including left atrial global longitudinal strain by speckle-tracking.\n\nPrimary objective: characterize the relationship between ACM and CKM syndrome stages using non-invasive parameters at first diagnosis. Secondary objectives include assessment of clinical, biological, ECG, and imaging profiles of ACM in CKM; evaluation of left atrial function across CKM stages; examination of Bayés interatrial block correlations and the impact of SGLT2 inhibitors and GLP-1 receptor agonists on left atrial remodeling in HFpEF; and identification of independent ACM risk factors incorporating the full biomarker panel.\n\nStatistical analyses include multivariable logistic regression, biomarker ROC analyses, and penalized regression for derivation of a pragmatic ACM risk score with internal validation. Expected outputs include prevalence estimates, effect sizes for ACM and CKM joint categories, biomarker performance metrics, and a clinic-ready checklist for risk-stratified prevention in outpatient settings.",[531,532,533,534,30],"Cardiovascular-Kidney-Metabolic Syndrome","Atrial Cardiomyopathy","Atrial Fibrillation","Chronic Kidney Disease",[536,537,538,539,540,541,542,543,544,533,534],"atrial cardiomyopathy","CKM syndrome","on-invasive evaluation","atrial remodeling","Bayés interatrial block","speckle tracking","Fetuin-A","MR-proANP","FGF23","2026-07-05",{"date":452,"type":44},{"date":548,"type":22},"2026-07-10",{"date":550,"type":22},"2028-04",{"name":552,"class":108},"Grigore T. Popa University of Medicine and Pharmacy",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":23,"phases":563,"briefSummary":564,"conditions":565,"keywords":580,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":52},"100643981","health-ahead-comparative-effectiveness-study-100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.",{"count":562,"type":22},1000000,[66],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[566,567,568,569,570,571,572,573,30,574,575,576,577,578,579],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Cardiovascular Diseases","Cognitive Dysfunction","Frailty","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[581,582,583,584,585,578,567,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":605,"type":44},"2026-06-25",{"date":607,"type":22},"2026-06-09",{"date":609,"type":22},"2099-12-31",{"name":611,"class":81},"William Brandenburg, MD",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":61,"sex":17,"minAge":620,"maxAge":408,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":623,"briefSummary":624,"conditions":625,"keywords":628,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":52},"100609572","our-voices-matter-intervention-for-depression-in-youth-100609572","NCT07216326","Our Voices Matter: Intervention for Depression in Youth","Our Voices Matter: Racial Justice Activism Intervention to Address Structural Racism and Prevent Depression in Black and Latinx Youth","OVM","Inclusion Criteria:\n\n1. 15-20 years old\n2. Identify as Black and\u002F or Latinx\n3. Speak English\n\nExclusion Criteria:\n\n1. Younger than 15 years old, or older than 20 years old\n2. Unable to attend the in-person sessions\n3. Non-fluent English speaker\n4. Do not identify as Black or Latinx","15 Years",{"count":622,"type":22},300,[66],"Over 15 million people participated in racial justice protests nationwide during 2020-2021 spotlighting activism as a collective tool against structural racism and discrimination (SRD). SRD manifests as policies and practices (e.g., redlining, voter suppression, mass incarceration) that produce hostile environments that contribute to psychological distress, elevated allostatic load, and an elevated risk for chronic diseases and premature death, concentrated within Black and Latinx populations. While the connection between SRD and health is well documented, few studies provide evidence on strategies to reduce SRD and mitigate consequences on psychological and physiological outcomes. Thus, there is a critical need to rigorously test interventions that improve the mental and physical health of Black and Latinx populations, beginning in adolescence. The study's specific aims are to 1) Determine whether a racial justice activism behavioral intervention prevents and reduces depressive symptoms in Black and Latinx adolescents and young adults and 2) Determine whether a racial justice activism behavioral intervention lowers allostatic load scores in Black and Latinx adolescents and young adults. To accomplish these aims, the team will conduct a stage II group-based, multi-component, and multilevel randomized behavioral clinical trial. The investigators will collect psychological and physiological measures at baseline, then at defined intervals for 2 years post the racial justice activism intervention.",[626,627,30],"Depressive Symptoms","Allostatic Load",[629,630,631,632,633,634,99,635,241],"mental health","youth intervention","allostatic load","stress","depressive symptoms","depression","prevention","2026-06-12",{"date":638,"type":44},"2026-06-15",{"date":640,"type":44},"2025-06-06",{"date":642,"type":22},"2028-12-29",{"name":644,"class":108},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":655,"conditions":656,"keywords":659,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":52},"100641794","personality-traits-and-biochemical-risk-phenotypes-100641794","NCT07653048","Personality Traits and Biochemical Risk Phenotypes","Personality Traits and Biochemical Risk Phenotypes in Adults Undergoing Routine Health Assessment","PHEBiP","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing routine health assessment\n* Completion of the Five-Factor Personality Inventory (FFPI)\n* Availability of routine laboratory test results\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Incomplete FFPI assessment\n* Missing or incomplete laboratory data\n* Refusal or inability to provide informed consent",{"count":654,"type":22},1000,"This prospective observational study investigates the association between personality traits and routine laboratory abnormalities in adults undergoing routine health assessment. Personality traits are assessed using the Five-Factor Personality Inventory (FFPI), while biochemical data are obtained from routine laboratory testing, including markers of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters.\n\nThe primary objective of the study is to evaluate the association between FFPI personality trait scores and the total number of laboratory abnormalities identified during routine clinical evaluation. Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers, lipid profile parameters, renal function indicators, complete blood count parameters, and the total number of laboratory abnormalities.\n\nThe findings may contribute to a better understanding of the relationship between psychological characteristics and biological health indicators and may support the development of more personalized approaches to health promotion, risk assessment, and disease prevention.",[657,658,30],"Prediabetes","Hyperglycemia",[660,661,657,658,662,663,664,665],"Personality Traits","Biomarkers","Occupational Health","Five-Factor Personality Inventory","Laboratory Abnormalities","Routine Health Assessment","2026-06-11",{"date":668,"type":44},"2026-06-17",{"date":670,"type":44},"2024-10-01",{"date":672,"type":22},"2027-09-01",{"name":674,"class":108},"Medical Center TOPMED",{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":681,"eligibilityCriteria":682,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":683,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":684,"conditions":685,"keywords":695,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":716,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":720,"locationsCount":52},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":562,"type":22},"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[572,686,687,599,573,688,574,30,575,689,690,391,576,577,691,692,693,578,694],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[696,697,698,699,700,701,702,703,704,705,706,707,708,578,709,710,589,590,587,597,711,712,713,714,715],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":638,"type":44},{"date":718,"type":44},"2026-04-25",{"date":609,"type":22},{"name":721,"class":81},"Longevity Metrics, Inc.",{"id":723,"slug":724,"hasResults":12,"nctId":725,"briefTitle":726,"officialTitle":727,"acronym":4,"eligibilityCriteria":728,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":729,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":730,"conditions":731,"keywords":737,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":743,"startDateStruct":744,"completionDateStruct":746,"leadSponsor":747,"locationsCount":52},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":562,"type":22},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[572,732,733,686,30,573,574,734,688,575,576,735,691,736,391],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[598,589,590,587,738,709,711,597,599,739,740,741,710,742,706,712],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":666,"type":44},{"date":745,"type":44},"2025-02-09",{"date":609,"type":22},{"name":721,"class":81},{"id":749,"slug":750,"hasResults":12,"nctId":751,"briefTitle":752,"officialTitle":753,"acronym":4,"eligibilityCriteria":754,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":755,"targetDuration":4,"studyType":23,"phases":757,"briefSummary":758,"conditions":759,"keywords":761,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":766,"startDateStruct":767,"completionDateStruct":769,"leadSponsor":771,"locationsCount":52},"100571091","theory-based-health-behaviour-change-intervention-in-individuals-of-metabolic-syndrome-with-chronic-kidney-disease-100571091","NCT06715735","Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease","The Effectiveness of A Theory-based Health Behaviour Change Intervention on Waist Circumference and Kidney Function in Patients of Metabolic Syndrome With Chronic Kidney Disease: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Participants are 18 years old and above;\n* Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol\u002FL or treatment for hypertriglycerides, HDL-C\\\u003C1.03 mmol\u002FL in men or \\\u003C1.29 mmol\u002FL in women or treatment for low HDL-C, FG ≥5.6 mmol\u002FL or previously diagnosed type 2 diabetes, and BP ≥ 130\u002F85 mmHg or treatment for hypertension), and CKD;\n* Participants are capable of understanding and providing informed consent, their cognitive function will be screened by the abbreviated mental test with a score higher than seven;\n* Own a smartphone for accessing WeChat;\n* Being able to communicate in Chinese.\n\nExclusion Criteria:\n\n* Participants who have medical contraindications to exercise, including walking;\n* Participants who have already started dialysis or kidney transplant;\n* Current participation in another clinical trial related to health behaviour change or medical trial;\n* Participants who have doctor-diagnosed psychiatric illness;\n* Adjustment of medication within half a year;\n* Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.",{"count":756,"type":22},160,[66],"This study will adopt a 2-arm, pretest-posttest, and assessor-blind RCT design to examine the effectiveness of a theory-based health behaviour change intervention on WC (primary outcome), kidney function (eGFR, primary outcome), dietary behaviour, PA, exercise capacity, and self-efficacy of dietary behaviour and PA among Chinese adults with metabolic syndrome and chronic kidney disease.\n\nA total of 160 adults with metabolic syndrome and chronic kidney disease will be recruited, with 80 participants in each group. Data will be collected at 3-time points (baseline, immediate post-intervention and 1-month post-intervention) via an online questionnaire survey platform (Qualtrics) by researchers blinded to the group allocation to reduce the detection bias.",[760,30],"Chronic Kidney Diseases",[30,534,762,763,764,765],"Waist Circumference","Kidney Function","Behaviour Change Intervention","Health Action Process Approach",{"date":666,"type":44},{"date":768,"type":44},"2024-12-20",{"date":770,"type":22},"2026-10-30",{"name":772,"class":108},"Chinese University of Hong Kong"]